



**Subject: Gastroenteropancreatic Neuroendocrine Tumors and Ki-67: References Included in the Evidence Table**

1. Abi-Raad R, Lavik JP, Barbieri AL, Zhang X, Adeniran AJ, Cai G. Grading pancreatic neuroendocrine tumors by ki-67 index evaluated on fine-needle aspiration cell block material. *Am J Clin Pathol.* 2020;153(1):74-81. doi:10.1093/ajcp/azq110
2. Adesoye T, Daleo MA, Loeffler AG, Winslow ER, Weber SM, Cho CS. Discordance of histologic grade between primary and metastatic neuroendocrine carcinomas. *Ann Surg Oncol.* 2015;22 Suppl 3(Suppl 3):S817-821. doi:10.1245/s10434-015-4733-7
3. Ahmed A, Turner G, King B et al. Midgut neuroendocrine tumours with liver metastases: Results of the ukinets study. *Endocr Relat Cancer.* 2009;16(3):885-894. doi:10.1677/ERC-09-0042
4. Keck KJ, Choi A, Maxwell JE et al. Increased grade in neuroendocrine tumor metastases negatively impacts survival. *Ann Surg Oncol.* 2017;24(8):2206-2212. doi:10.1245/s10434-017-5899-y
5. McCall CM, Shi C, Cornish TC et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both ki67 proliferative index and mitotic rate. *Am J Surg Pathol.* 2013;37(11):1671-1677. doi:10.1097/PAS.0000000000000089
6. Owens R, Gilmore E, Bingham V et al. Comparison of different anti-ki67 antibody clones and hot-spot sizes for assessing proliferative index and grading in pancreatic neuroendocrine tumours using manual and image analysis. *Histopathology.* 2020;77(4):646-658. doi:10.1111/his.14200
7. Shi C, Gonzalez RS, Zhao Z et al. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and world health organization grade discordance with primary tumors. *Am J Clin Pathol.* 2015;143(3):398-404. doi:10.1309/AJCPQ55SKOCYFZHN
8. Sugimoto S, Hotta K, Shimoda T et al. Can the ki-67 labeling index in biopsy specimens predict the world health organization grade of rectal neuroendocrine tumors? *Dig Dis.* 2018;36(2):118-122. doi:10.1159/000484083
9. Tacelli M, Bina N, Crino SF et al. Reliability of grading preoperative pancreatic neuroendocrine tumors on eus specimens: A systematic review with meta-analysis of aggregate and individual data. *Gastrointest Endosc.* 2022;96(6):898-908 e823. doi:10.1016/j.gie.2022.07.014
10. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: A comparison of digital image analysis with manual methods. *Am J Surg Pathol.* 2012;36(12):1761-1770. doi:10.1097/PAS.0b013e318263207c
11. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: Implications for prognostic stratification. *Am J Surg Pathol.* 2011;35(6):853-860. doi:10.1097/PAS.0b013e31821a0696
12. Appelstrand A, Bergstedt F, Elf AK, Fagman H, Hedenstrom P. Endoscopic ultrasound-guided side-fenestrated needle biopsy sampling is sensitive for pancreatic neuroendocrine tumors but inadequate for tumor grading: A prospective study. *Sci Rep.* 2022;12(1):5971. doi:10.1038/s41598-022-09923-1
13. Botling J, Lamarca A, Bajic D et al. High-grade progression confers poor survival in pancreatic neuroendocrine tumors. *Neuroendocrinology.* 2020;110(11-12):891-898. doi:10.1159/000504392

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed on April 14, 2025.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations. These draft materials should not be stored, adapted, or redistributed in any manner.

Please note: comments are not posted automatically. All comments will be posted on a weekly basis beginning March 24, 2025.

14. Burad DK, Kodiatte TA, Rajeeb SM, Goel A, Eapen CE, Ramakrishna B. Neuroendocrine neoplasms of liver - a 5-year retrospective clinico-pathological study applying world health organization 2010 classification. *World J Gastroenterol.* 2016;22(40):8956-8966.
15. Conemans EB, Brosens LAA, Raicu-Ionita GM et al. Prognostic value of who grade in pancreatic neuro-endocrine tumors in multiple endocrine neoplasia type 1: Results from the dutchmen1 study group. *Pancreatology.* 2017;17(5):766-772. doi:10.1016/j.pan.2017.07.196
16. Cottenden J, Filter ER, Cottreau J et al. Validation of a cytotechnologist manual counting service for the ki67 index in neuroendocrine tumors of the pancreas and gastrointestinal tract. *Arch Pathol Lab Med.* 2018;142(3):402-407. doi:10.5858/arpa.2017-0203-OA
17. Dere Y, Ozkaraca O, Cetin G, Dere O. Evaluation of an image-based automated detection system in detecting ki67 proliferation index and correlation with the traditional eye-ball method in gastroenteropancreatic neuroendocrine tumors. *J Coll Physicians Surg Pak.* 2019;29(2):137-140. doi:10.29271/jcpsp.2019.02.137
18. Dhall D, Mertens R, Bresee C et al. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. *Hum Pathol.* 2012;43(4):489-495. doi:10.1016/j.humpath.2011.06.011
19. Dogukan FM, Yilmaz Ozguven B, Dogukan R, Kabukcuoglu F. Comparison of monitor-image and printout-image methods in ki-67 scoring of gastroenteropancreatic neuroendocrine tumors. *Endocr Pathol.* 2019;30(1):17-23. doi:10.1007/s12022-018-9554-3
20. Dumars C, Foubert F, Touchefeu Y et al. Can pph3 be helpful to assess the discordant grade in primary and metastatic enteropancreatic neuroendocrine tumors? *Endocrine.* 2016;53(2):395-401. doi:10.1007/s12020-016-0944-3
21. Furukawa T, Ozaka M, Takamatsu M et al. Ki-67 labeling index variability between surgically resected primary and metastatic hepatic lesions of gastroenteropancreatic neuroendocrine neoplasms. *Int J Surg Pathol.* 2021;29(5):475-481. doi:10.1177/1066896921990715
22. Grillo F, Albertelli M, Brisigotti MP et al. Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor. *Neuroendocrinology.* 2016;103(5):452-459. doi:10.1159/000439434
23. Hacking SM, Sajjan S, Lee L et al. Potential pitfalls in diagnostic digital image analysis: Experience with ki-67 and pph3 in gastrointestinal neuroendocrine tumors. *Pathol Res Pract.* 2020;216(3):152753. doi:10.1016/j.prp.2019.152753
24. Heidsma CM, Tsilimigras DI, Rocha F et al. Clinical relevance of performing endoscopic ultrasound-guided fine-needle biopsy for pancreatic neuroendocrine tumors less than 2 cm. *J Surg Oncol.* 2020;122(7):1393-1400. doi:10.1002/jso.26158
25. Jin M, Roth R, Gayetsky V, Niederberger N, Lehman A, Wakely PE, Jr. Grading pancreatic neuroendocrine neoplasms by ki-67 staining on cytology cell blocks: Manual count and digital image analysis of 58 cases. *J Am Soc Cytopathol.* 2016;5(5):286-295. doi:10.1016/j.jasc.2016.03.002
26. Kankava K, Maisonneuve P, Mangogna A et al. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties. *J Neuroendocrinol.* 2021;33(8):e13000. doi:10.1111/jne.13000
27. Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T. A comparison of ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. *Br J Cancer.* 2013;108(9):1838-1845. doi:10.1038/bjc.2013.156
28. Komac O, Bengi G, Sagol O, Akarsu M. C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group. *World J Gastrointest Oncol.* 2019;11(2):139-152. doi:10.4251/wjgo.v11.i2.139
29. Kroneman TN, Voss JS, Lohse CM, Wu TT, Smyrk TC, Zhang L. Comparison of three ki-67 index quantification methods and clinical significance in pancreatic neuroendocrine tumors. *Endocr Pathol.* 2015;26(3):255-262. doi:10.1007/s12022-015-9379-2

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed on April 14, 2025.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations. These draft materials should not be stored, adapted, or redistributed in any manner.

Please note: comments are not posted automatically. All comments will be posted on a weekly basis beginning March 24, 2025.

30. Landerholm K, Falkmer SE. Ki-67 index and solid growth pattern as prognostic markers in small intestinal neuroendocrine tumors. *Neuroendocrinology*. 2015;102(4):327-334. doi:10.1159/000434724
31. Lea D, Gudlaugsson EG, Skaland I, Lillesand M, Soreide K, Soreide JA. Digital image analysis of the proliferation markers ki67 and phosphohistone h3 in gastroenteropancreatic neuroendocrine neoplasms: Accuracy of grading compared with routine manual hot spot evaluation of the ki67 index. *Appl Immunohistochem Mol Morphol*. 2021;29(7):499-505. doi:10.1097/PAI.0000000000000934
32. Lv Y, Han X, Xu XF et al. Risk factors affecting prognosis in metachronous liver metastases from who classification g1 and g2 gastroenteropancreatic neuroendocrine tumors after initial r0 surgical resection. *BMC Cancer*. 2019;19(1):335. doi:10.1186/s12885-019-5457-z
33. Martin-Perez E, Capdevila J, Castellano D et al. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the spanish national tumor registry (rgetne). *Neuroendocrinology*. 2013;98(2):156-168. doi:10.1159/000355152
34. Mastrosimini MG, Manfrin E, Remo A et al. Endoscopic ultrasound fine-needle biopsy to assess daxx/atrx expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors. *Pancreatology*. 2023;23(4):429-436. doi:10.1016/j.pan.2023.05.002
35. Murphy CE, McCormick KA, Shankaran V et al. Grade assignment by ki-67 proliferative index, mitotic count, and phosphohistone h3 count in surgically resected gastrointestinal and pancreatic neuroendocrine tumors. *Pancreas*. 2017;46(10):1359-1365. doi:10.1097/MPA.0000000000000923
36. Nadler A, Cukier M, Rowsell C et al. Ki-67 is a reliable pathological grading marker for neuroendocrine tumors. *Virchows Arch*. 2013;462(5):501-505. doi:10.1007/s00428-013-1410-8
37. Paiella S, Landoni L, Rota R et al. Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors: A retrospective analysis of 110 cases. *Endoscopy*. 2020;52(11):988-994. doi:10.1055/a-1180-8614
38. Park JH, Shin SJ, Jeon N, Lim BJ. Clinicopathologic characteristics of neuroendocrine tumors with assessment by digital image analysis for ki-67 index with a focus on the gastroenteropancreatic tract: A single-center study. *Int J Clin Exp Pathol*. 2023;16(9):225-234.
39. Philips P, Kooby DA, Maithel S et al. Grading using ki-67 index and mitotic rate increases the prognostic accuracy of pancreatic neuroendocrine tumors. *Pancreas*. 2018;47(3):326-331. doi:10.1097/MPA.0000000000000990
40. Reid MD, Bagci P, Ohike N et al. Calculation of the ki67 index in pancreatic neuroendocrine tumors: A comparative analysis of four counting methodologies. *Mod Pathol*. 2015;28(5):686-694. doi:10.1038/modpathol.2014.156
41. Remes SM, Tuominen VJ, Helin H, Isola J, Arola J. Grading of neuroendocrine tumors with ki-67 requires high-quality assessment practices. *Am J Surg Pathol*. 2012;36(9):1359-1363. doi:10.1097/PAS.0b013e3182632038
42. Saadeh H, Abdullah N, Erashdi M, Sughayer M, Al-Kadi O. Histopathologist-level quantification of ki-67 immunoexpression in gastroenteropancreatic neuroendocrine tumors using semiautomated method. *J Med Imaging (Bellingham)*. 2020;7(1):012704. doi:10.1117/1.JMI.7.1.012704
43. Saetiew K, Angkathunyakul N, Hunnangkul S, Pongpaibul A. Digital image analysis of ki67 hotspot detection and index counting in gastroenteropancreatic neuroendocrine neoplasms. *Ann Diagn Pathol*. 2024;71:152295. doi:10.1016/j.anndiagpath.2024.152295
44. Satturwar SP, Pantanowitz JL, Manko CD, Seigh L, Monaco SE, Pantanowitz L. Ki-67 proliferation index in neuroendocrine tumors: Can augmented reality microscopy with image analysis improve scoring? *Cancer Cytopathol*. 2020;128(8):535-544. doi:10.1002/cncy.22272
45. Shaker N, Shen R, Limbach AL et al. Automated imaging analysis of ki-67 immunohistochemistry on whole slide images of cell blocks from pancreatic neuroendocrine neoplasms. *J Am Soc Cytopathol*. 2024;13(3):205-212. doi:10.1016/j.jasc.2024.02.001

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed on April 14, 2025.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations. These draft materials should not be stored, adapted, or redistributed in any manner.

Please note: comments are not posted automatically. All comments will be posted on a weekly basis beginning March 24, 2025.

46. Shi H, Jiang C, Zhang Q, Qi C, Yao H, Lin R. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm. *Diagn Pathol*. 2020;15(1): 108. doi:10.1186/s13000-020-01030-x
47. Shi H, Zhang Q, Han C, Zhen D, Lin R. Variability of the ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study. *BMC Endocr Disord*. 2018;18(1):51.
48. Sigel CS, Guo H, Sigel KM et al. Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms. *Cancer Cytopathol*. 2017;125(3):188-196. doi:10.1002/cncy.21817
49. Singh S, Hallet J, Rowsell C, Law CH. Variability of ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease. *Eur J Surg Oncol*. 2014;40(11):1517-1522. doi:10.1016/j.ejso.2014.06.016
50. Tracht J, Zhang K, Peker D. Grading and prognostication of neuroendocrine tumors of the pancreas: A comparison study of ki67 and phh3. *J Histochem Cytochem*. 2017;65(7):399-405. doi:10.1369/0022155417708186
51. Zen Y, Heaton N. Elevated ki-67 labeling index in 'synchronous liver metastases' of well differentiated enteropancreatic neuroendocrine tumor. *Pathol Int*. 2013;63(11):532-538. doi:10.1111/pin.12108
52. Zhang M, Tan C, Wang X et al. Digital image analysis of ki67 heterogeneity improves the diagnosis and prognosis of gastroenteropancreatic neuroendocrine neoplasms. *Mod Pathol*. 2023;36(1):100017. doi:10.1016/j.modpat.2022.100017
53. Zhang WH, Gao HL, Liu WS et al. A real-life treatment cohort of pancreatic neuroendocrine tumors: High-grade increase in metastases confers poor survival. *Front Endocrinol (Lausanne)*. 2022;13:941210. doi:10.3389/fendo.2022.941210
54. Zhao CL, Dabiri B, Hanna I et al. Improving fine needle aspiration to predict the tumor biological aggressiveness in pancreatic neuroendocrine tumors using ki-67 proliferation index, phosphorylated histone h3 (phh3), and bcl-2. *Ann Diagn Pathol*. 2023;65:152149. doi:10.1016/j.anndiagpath.2023.152149
55. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histological samples obtained by eus-guided fine-needle tissue acquisition: A prospective study (gastrointestinal endoscopy (2012) 76, (570-577)). *Gastrointest Endosc*. 2012;76(5):1085. <http://dx.doi.org/10.1016/j.gie.2012.09.005>

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only. The draft recommendations and supporting documents will be removed on April 14, 2025.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations. These draft materials should not be stored, adapted, or redistributed in any manner.

Please note: comments are not posted automatically. All comments will be posted on a weekly basis beginning March 24, 2025.